Merdury Biopharmaceutical

Merdury Biopharmaceutical PEG

PEG Ratio (Price/Earnings-to-Growth) of Merdury Biopharmaceutical (6932.TWO) as of Oct 18, 2026.

PEG

-

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Merdury Biopharmaceutical is 2026 - . PEG Ratio (Price/Earnings-to-Growth) of Merdury Biopharmaceutical was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Merdury Biopharmaceutical Stock analysis

What does Merdury Biopharmaceutical do? Merdury Biopharmaceutical Corp is a pharmaceutical company based in Taipei, Taiwan, operating within the Health Care sector. The company has a small workforce of 13 employees and went public on December 23, 2022, with its ticker listed as 6932.TWO. Merdury Biopharmaceutical Corp focuses on developing drugs that address unmet medical needs, difficult generic drugs, and second-class new drugs. The company utilizes a self-developed drug development platform called StackDose, which enables the creation of tablets with controlled dissolution properties, allowing for either immediate or sustained drug release. This technology supports the development of products such as Sildenafil, Metformin, Tadalafil, Zolpidem, angina treatments, migraine medications, and multi-ingredient antihypertensive drugs. These products are primarily marketed and sold in Taiwan and the United States. The company's website is https://merdury.com, providing further information about its operations and offerings. Merdury Biopharmaceutical Corp operates as a publicly traded entity with a focus on innovative pharmaceutical solutions within the Taiwanese and U.S. markets. Merdury Biopharmaceutical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Merdury Biopharmaceutical stock

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Merdury Biopharmaceutical since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Merdury Biopharmaceutical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Merdury Biopharmaceutical

All Key Metrics — Merdury Biopharmaceutical